Quarterly report pursuant to Section 13 or 15(d)

Oxford Finance Loan Agreement - Additional Information (Details)

v3.24.1.1.u2
Oxford Finance Loan Agreement - Additional Information (Details) - USD ($)
3 Months Ended
Nov. 15, 2022
Jul. 03, 2022
Jul. 02, 2022
Feb. 12, 2020
Mar. 31, 2024
Mar. 31, 2023
Dec. 23, 2020
Debt Instrument [Line Items]              
Term loan         $ 40,000,000    
Loan Agreement              
Debt Instrument [Line Items]              
Term loan, aggregate principal amount       $ 60,000,000.0      
Additional term loan advances, description       A $20.0 million term loan (first tranche) was funded on February 12, 2020, and another $20.0 million term loan (second tranche) was funded on December 23, 2020. As of March 31, 2024, the final $20.0 million tranche remained available under the Loan Agreement, at the sole discretion of the Lender.      
Each of available additional term loan advances         $ 20,000,000.0    
Term loan, interest rate terms the floating annual rate for each term loan was amended to equal the greater of (i) 7.75% and (ii) the sum of (a) the 1-month CME Term SOFR reference rate, (b) 0.10%, and (c) 5.98%. On May 9, 2024, the Company entered into a further amendment to the Loan Agreement with the Lender (refer to Note 12).     The term loan initially bore interest at an annual rate equal to the greater of (i) 7.75% and (ii) the sum of 5.98% and the greater of (A) one-month LIBOR or (B) 1.77%.      
Term loan, interest rate 7.75%     7.75%      
Term loan, effective interest rate 5.98%     5.98%      
Term loan, variable interest rate basis 1-month CME Term SOFR     one-month LIBOR      
Term loan, variable interest rate basis spread 0.10%     1.77%      
Term loan, maturity date       Feb. 01, 2025      
Extended interest only period upon consummation of merger and private placement   Mar. 01, 2024 Mar. 01, 2023        
Extended maturity date upon consummation of merger and private placement   Feb. 01, 2026 Feb. 01, 2025        
Extended interest only period upon achievement of certain milestones   Sep. 01, 2024          
Extended maturity upon consummation of merger and private placement   Aug. 01, 2026          
Term Loan, facilities fee       $ 300,000      
Term loan, final payment fee percentage       5.00%      
Warrant exercisable period from date of issuance         5 years    
Interest expense         $ 1,300,000 $ 1,200,000  
Loan Agreement | Advance Prepaid in First 12 Months              
Debt Instrument [Line Items]              
Term loan, prepayment fee, equal to percentage of the principal amount being prepaid       2.00%      
Loan Agreement | Advance Prepaid After 12 Months But Prior to 24 Months              
Debt Instrument [Line Items]              
Term loan, prepayment fee, equal to percentage of the principal amount being prepaid       1.00%      
Loan Agreement | Advance Prepaid After 24 Months But Prior to Maturity Date              
Debt Instrument [Line Items]              
Term loan, prepayment fee, equal to percentage of the principal amount being prepaid       0.50%      
Loan Agreement | First Loan Tranche              
Debt Instrument [Line Items]              
Term loan       $ 20,000,000.0      
Term Loan, facilities fee       $ 100,000      
Warrants issued to purchase common stock       2,754      
Warrant exercise price of common stock per share       $ 72.60      
Loan Agreement | Second Loan Tranche              
Debt Instrument [Line Items]              
Term loan             $ 20,000,000.0
Term Loan, facilities fee             $ 75,000
Warrants issued to purchase common stock             1,738
Warrant exercise price of common stock per share             $ 115.00
Loan Agreement | Third Loan Tranche              
Debt Instrument [Line Items]              
Term loan, facilities fee       $ 50,000